🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Cytek Biosciences, Inc. CTKB R2K

Healthcare · Medical Devices · United States
https://cytekbio.com

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

READ MORE ›
$4.19
+51.26% 1Y

Market & Price

Market Cap
$541.11M
Current Price
$4.19
High / Low (52W)
$5.88 / $2.77
Beta
1.23

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
22.05
PEG Ratio
-
Book Value
$2.54
Price to Book
1.65
P/S
2.65
EV/EBITDA
-8.44
Dividend Yield
-

Profitability & Returns

ROCE
-7.65%
ROE
-20.93%
ROA
-5.89%
Profit Margin
-36.25%
Op Margin
-41.83%
EPS (Latest Qtr)
$-0.15
EPS (TTM)
$-0.58

Balance Sheet & Liquidity

Debt/Equity
0.08
Quick Ratio
3.94
Current Ratio
4.69
Debt
$27.48M
Total Assets
$461.54M
Current Assets
$392.00M
Working Capital
$314.19M

Ownership

Promoter Holding
8.43%
Chg in Prom Hold
-
FII / Inst Holding
67.58%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$306.36M
Total Revenue (TTM)
$204.17M
EBITDA
$-36.30M
Free Cash Flow
$6.41M
Operating Cash Flow
$-7.30M
Shares Outstanding
129.14M
Gross Margin
51.70%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
7.10%
Profit 5Y
-894.35%
Revenue (YoY)
6.50%
Earnings (YoY)
-

PROS

  • Generates positive free cash flow.

CONS

  • Earnings shrank at -894.3% CAGR over 5 years.
  • Trading 28.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CTKB Cytek Biosciences, Inc. R2K 4.19 - $541.11M - -7.65% -20.93% 7.10% -894.35%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 41.46M45.60M52.29M62.14M44.13M
Cost of Revenue 21.30M21.73M24.74M29.26M22.88M
Gross Profit 20.16M23.87M27.55M32.88M21.25M
Operating Expenses 35.13M34.49M36.74M38.48M39.72M
Operating Income -14.97M-10.62M-9.19M-5.59M-18.46M
EBITDA -8.09M-3.37M-4.21M-1.71M-14.30M
Interest Expense 291.00K414.00K494.00K-725.00K262.00K
Pretax Income -11.27M-6.78M-7.77M-4.03M-17.37M
Tax Provision 136.00K-1.19M-2.29M40.05M1.49M
Net Income -11.40M-5.58M-5.48M-44.08M-18.87M
Diluted EPS -0.09-0.04-0.04-0.34-0.15

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -164.04M193.01M200.45M201.49M
Cost of Revenue -63.06M83.59M89.35M97.03M
Gross Profit -100.97M109.43M111.11M104.46M
Operating Expenses -102.78M137.27M131.63M144.84M
Operating Income --1.80M-27.84M-20.52M-40.38M
EBITDA -9.49M-4.41M-10.03M-17.39M
Interest Expense 1.74M2.57M2.07M-474.00K
Pretax Income -1.26M-15.71M-5.70M-29.84M
Tax Provision --1.22M-3.56M320.00K36.70M
Net Income -2.58M-12.15M-6.02M-66.54M
Diluted EPS -0.02-0.09-0.05-0.52

Compounded Sales Growth

5 Years:7.10%
1 Year:6.50%

Compounded Profit Growth

5 Years:-894.35%
1 Year:-

Stock Price Performance

1 Year:+51.26%
6 Months:-28.01%
3 Months:-6.47%
1 Month:-5.63%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -519.48M494.46M499.50M461.54M
Current Assets -454.02M392.06M396.45M392.00M
Cash & Equivalents -296.60M167.30M98.72M90.85M
Inventory -48.15M60.88M43.89M48.43M
Receivables -48.86M55.93M60.59M62.51M
Total Liabilities -93.93M101.39M103.76M119.80M
Current Liabilities -49.04M56.23M67.66M77.80M
Long Term Debt -2.27M1.65M1.05M525.00K
Total Debt -18.09M14.14M17.02M23.74M
Total Equity -425.30M393.06M395.74M341.74M
Shares Outstanding -135.37M130.71M129.21M128.55M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --12.23M5.28M25.38M-4.69M
Investing Cash Flow --55.91M-93.89M-82.97M10.12M
Financing Cash Flow -5.51M-41.81M-15.82M-13.43M
Capital Expenditure --9.87M-4.83M-3.73M-4.19M
Free Cash Flow --22.10M454.00K21.65M-8.88M
Net Change in Cash --62.63M-130.43M-73.42M-8.00M

Ratios (Annual)

Figures in %.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -61.6%56.7%55.4%51.8%
Operating Margin % --1.1%-14.4%-10.2%-20.0%
Net Margin % -1.6%-6.3%-3.0%-33.0%
ROE % -0.6%-3.1%-1.5%-19.5%
ROCE % --0.4%-6.4%-4.8%-10.5%

Shareholding Pattern

Insiders
8.43%
Institutions
67.58%
Public Float
73.81%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 13.17% 17.01M $71.26M
2 Topline Capital Management, LLC 5.47% 7.06M $29.60M
3 HHLR Advisors, LTD 5.15% 6.66M $27.89M
4 Millennium Management Llc 4.87% 6.29M $26.36M
5 Boston Partners 4.49% 5.80M $24.31M
6 Vanguard Capital Management LLC 3.69% 4.76M $19.96M
7 State Street Corporation 3.19% 4.12M $17.28M
8 Geode Capital Management, LLC 2.19% 2.83M $11.87M
9 Dimensional Fund Advisors LP 2.06% 2.66M $11.16M
10 Goldman Sachs Group Inc 1.82% 2.34M $9.82M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CTKB

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks